Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074059 · ClinicalTrials.gov registry record · Phase 2
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02074059: Completed Phase 2 study, sponsored by Windtree Therapeutics.
NCT02074059 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02074059, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to neonates receiving nCPAP alone.
Primary Outcome
Pre-specified adverse events that occured during treatment administration; does not include nCPAP alone
Interventions
- DRUG Lucinactant for Inhalation
- DEVICE nCPAP alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
What the finished NCT02074059 record still lists
NCT02074059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Lucinactant for Inhalation is the first listed.
NCT02074059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02074059 about?
NCT02074059 is a clinical study titled "Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates". The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks gestational age who are receiving nasal continuous positive airway pressure (...
What is the current status of trial NCT02074059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2014-02. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02074059?
The interventions under investigation include: Lucinactant for Inhalation (DRUG), nCPAP alone (DEVICE).
Who is sponsoring clinical trial NCT02074059?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02074059's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia